Clinical trial NCT03422510: FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Official title: A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primary Focal Segmental Glomerulosclerosis
Keywords: FSGS
Kidney Disease
Proteinuria
Nephrotic Syndrome
FIRSTx
Nitro fatty acids
OA-NO2
10-nitro oleic acid
Nitro oleic acid
Lead sponsor: Complexa, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Kidney Research Network, formerly NephCure Accelerating Cures Institute
name: Medpace, Inc.
name: MicroConstants
name: Arkana Labs
name: NephCure Kidney International
First posted: 2018-02-05
Enrollment: 33
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.

The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipated to be up to approximately 16 months. Approximately 30 subjects will be randomized to ensure 26 subjects complete the study. An optional 9 month open label is available

Detailed description: This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.

The study will be performed at approximately 25 study centers across the United States of America (USA). The recruitment period is anticipated to be up to approximately 16 months. Approximately 30 subjects will be randomized.

Study participation for each subject will last up to 5 months. The study will consist of a screening period not to exceed 30 days (1 month), 90-day (3 month) treatment period, and an approximate 28-day (1 month) follow-up period after the last dose of study medication. An optional 9 month open label is available.

Eligibility criteria: Inclusion Criteria:

1. have a diagnosis of primary FSGS confirmed with biopsy.
2. eGFR or 24-hour creatinine clearance ≥ 40 mL/min/1.73 m2 at Screening.
3. The subject has a Up/c ratio ≥ 2 g protein/g creatinine based on a 24 hour urine sample collected during Screening (one 24-hour collection between Day -30 and Day -8).
4. Unless there is an allergy or intolerance, subject must be on an ACEi and/or ARB regimen for a minimum of 4 weeks prior to their screening Up/c assessment. The ACEi and/or ARB regimen must be stable for a minimum of 2 weeks prior to screening Up/c assessment (and there are no plans to change the ACEi/ARB regimen over the course of the study).
5. If receiving simvastatin containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, the simvastatin dose should not exceed 20 mg/day.
6. Non-pregnant, non-lactating, female of childbearing potential who agrees to use a reliable method of contraception or female is of non-childbearing potential defined as surgically sterile (hysterectomy or bilateral tubal ligation) or post-menopausal.

Exclusion Criteria:

1. The subject has collapsing variant of FSGS on renal biopsy.
2. The subject has secondary FSGS.
3. The subject has diabetic nephropathy.
4. The subject has any other form of acquired (including biopsy proven obesity-induced FSGS) or hereditary glomerular nephropathy.
5. The subject has a prolonged QTcF interval.
6. The subject is hypertensive.
7. The subject has a history of clinically significant cardiovascular events, arrhythmias, recurrent fainting, palpitations, or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason.
8. The subject has any known bleeding disorders or significant active peptic ulceration in the opinion of the investigator that precludes enrollment into this study.
9. The subject has clinically significant anemia in the opinion of the investigator that precludes enrollment into this study.
10. The subject has a history of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of the following:

    1. Basal cell or squamous cell carcinomas of the skin,
    2. Cervical carcinoma in situ,
    3. Other malignancies curatively treated and with no evidence of disease for at least 5 years, or
    4. Prostate cancer which is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment.
11. The subject has a history of organ transplantation.
12. The subject has a history of HIV.
13. At the time of Screening (Visit 1), the subject has any co-existing disease or condition.
14. Since the time of presentation of symptoms/diagnosis of FSGS: the subject has received systemic (oral or parenteral) high-dose, long-term corticosteroid therapy (prednisone or alternative glucocorticoid) to treat kidney disease
15. Subject has a history of immunosuppressant therapy (calcineurin inhibitors, rituximab, or other non-steroid immunosuppressants).
16. The subject has a history of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline
17. The subject is currently taking a drug that may affect the measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium).
18. The subject is currently taking a newly prescribed drug or new prescription for an increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de pointes (a list is provided in Appendix H). Note: Stable doses of these drugs are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Screening \[Visit 1\] with no anticipated changes to the dose or regimen during the study).
19. The subject is currently taking endothelin receptor antagonists, dimethyl fumarate (Tecfidera™), orlistat, fibrates (fenofibrate, bezafibrate, gemfibrozil and ciprofibrate), niacin or lomatapide.
20. The subject has any of the following abnormal laboratories at Screening:

    1. Serologic evidence of HIV, hepatitis B, or hepatitis C based on HIV antibody, HBsAg, and HCV Ab,
    2. Absolute lymphocyte counts below the lower limit of normal of the reference range
    3. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3.0X upper limit of normal (ULN), alkaline phosphatase \> 2X ULN of liver origin, and total bilirubin \>2X ULN. If all LFTs are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted to evaluate for Rotor's/Gilbert's Syndrome. Subjects with Rotor's/Gilbert's Syndrome may be enrolled.
21. Female subject with a positive urine beta-human chorionic gonadotropin (β-hCG) test at Screening (Visit 1) (all females) or Baseline (Visit 2) (females of childbearing potential or with a history of bilateral tubal ligation in the absence of documented menopause).
22. The subject has received a live attenuated vaccine within 6 weeks prior to Baseline (Visit 2) or plans to receive a live attenuated vaccine during the study period.
23. The subject has a recent history (within one year prior to Screening \[Visit 1\]) of abusing alcohol or illicit drugs (including marijuana) or history of extensive illicit intravenous drug use.
24. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures).
25. The subject has known hypersensitivity to CXA-10, its metabolites, or formulation excipients.
26. The subject has had treatment with any investigational drug or device within 30 days or 5 half-lives (whichever is longer) prior to Screening (Visit 1) (this includes investigational formulations of marketed products, inhaled and topical drugs), or plans to participate in another investigational drug or device study at any time during this study.
27. The subject weighs \< 40 kg

Primary outcomes:
measure: Reduction in proteinuria
timeFrame: 3 months
Secondary outcomes:
measure: The percent of subjects with of partial remission, modified partial remission, and complete remission
timeFrame: months 1, 2, 3
Other outcomes:
Locations:
city: Huntsville
country: United States
facility: Alabama Neurology Consultants
state: Alabama
city: Los Angeles
country: United States
facility: Cedars Sinai Medical Center
state: California
city: Palo Alto
country: United States
facility: Stanford University
state: California
city: Wilmington
country: United States
facility: A.I. duPont Hospital for Children
state: Delaware
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Chicago
country: United States
facility: Nephrology Associates of Northern Illinois and Indiana (NANI)
state: Illinois
city: Shreveport
country: United States
facility: Northwest Louisiana Nephrology
state: Louisiana
city: Springfield
country: United States
facility: Kidney Care and Transplant Services of New England
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Roseville
country: United States
facility: St. Clair Nephrology Research
state: Michigan
city: Kansas City
country: United States
facility: Clinical Research Consultants-KCMO
state: Missouri
city: Bronx
country: United States
facility: Albert Einstein College of Medicine, Montefiore
state: New York
city: Charlotte
country: United States
facility: Metrolina Nephrology Associates
state: North Carolina
city: Charlotte
country: United States
facility: Levine Children's Hospital
state: North Carolina
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Bethlehem
country: United States
facility: Northeast Clinical Research Center (NCRC)
state: Pennsylvania
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Franklin
country: United States
facility: Nephrology Associates
state: Tennessee
city: Amarillo
country: United States
facility: Texas Tech
state: Texas
city: DeSoto
country: United States
facility: Renal Disease Research Institute
state: Texas
city: El Paso
country: United States
facility: El Paso Medical Research
state: Texas
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: Seattle
country: United States
facility: The Polyclinic
state: Washington
city: Spokane
country: United States
facility: Providence Sacred Heart Medical Center and Children's Hospital
state: Washington
Study officials:
affiliation: Complexa, Inc.
name: Theodore Danoff, MD
role: STUDY_DIRECTOR
References: